Stock Analysis

Lunit And Two Other Stocks Believed To Be Trading Below Estimated Value

SWX:SRAIL
Source: Shutterstock

As global markets navigate a mixed economic landscape, with U.S. consumer confidence dipping and European stocks seeing modest gains, investors are keenly assessing opportunities amidst fluctuating indices. In such an environment, identifying undervalued stocks can be crucial for those looking to capitalize on discrepancies between market price and intrinsic value, offering potential for future growth when broader market conditions stabilize.

Top 10 Undervalued Stocks Based On Cash Flows

NameCurrent PriceFair Value (Est)Discount (Est)
Corporativo Fragua. de (BMV:FRAGUA B)MX$631.28MX$1257.0749.8%
Round One (TSE:4680)¥1310.00¥2617.5750%
SKS Technologies Group (ASX:SKS)A$1.935A$3.8649.8%
S Foods (TSE:2292)¥2745.00¥5472.3549.8%
Cettire (ASX:CTT)A$1.51A$3.0249.9%
Medley (TSE:4480)¥3835.00¥7615.9849.6%
Surgical Science Sweden (OM:SUS)SEK159.60SEK317.2049.7%
Beijing LeiKe Defense Technology (SZSE:002413)CN¥4.53CN¥9.0149.7%
SkyCity Entertainment Group (NZSE:SKC)NZ$1.45NZ$2.9049.9%
Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266)CN¥63.53CN¥126.4649.8%

Click here to see the full list of 874 stocks from our Undervalued Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

Lunit (KOSDAQ:A328130)

Overview: Lunit Inc. is a South Korean company that offers AI-powered software and solutions for cancer diagnostics and therapeutics, with a market cap of ₩1.77 trillion.

Operations: The company's revenue is primarily derived from its healthcare software segment, which generated ₩39.54 billion.

Estimated Discount To Fair Value: 27.1%

Lunit's stock appears significantly undervalued, trading over 20% below its estimated fair value of ₩87,499.34. Despite a volatile share price recently, the company is poised for high revenue growth at 49.9% annually, surpassing market averages. Lunit's recent advancements in AI technology and strategic partnerships enhance its competitive edge in oncology diagnostics and global market expansion. However, its low future return on equity forecast may be a concern for some investors.

KOSDAQ:A328130 Discounted Cash Flow as at Dec 2024
KOSDAQ:A328130 Discounted Cash Flow as at Dec 2024

Stadler Rail (SWX:SRAIL)

Overview: Stadler Rail AG is a company that manufactures and sells trains across Switzerland, Germany, Austria, various parts of Europe, the Americas, and CIS countries with a market cap of CHF2 billion.

Operations: Stadler Rail AG generates revenue primarily from Rolling Stock (CHF3.10 billion), followed by Service & Components (CHF789.41 million), and Signalling (CHF135.68 million).

Estimated Discount To Fair Value: 46.7%

Stadler Rail is trading at CHF20, significantly below its estimated fair value of CHF37.55, indicating it may be undervalued based on cash flows. Earnings are projected to grow substantially at 22.9% annually, outpacing the Swiss market's average growth rate. However, the dividend yield of 4.5% isn't well covered by free cash flows, and future return on equity is forecast to remain modest at 18.7%, which could be a concern for some investors.

SWX:SRAIL Discounted Cash Flow as at Dec 2024
SWX:SRAIL Discounted Cash Flow as at Dec 2024

TORIDOLL Holdings (TSE:3397)

Overview: TORIDOLL Holdings Corporation operates and manages restaurants both in Japan and internationally, with a market cap of ¥336.66 billion.

Operations: The company's revenue segments include Marugame Seimen generating ¥121.61 billion, and the Overseas Business contributing ¥99.74 billion.

Estimated Discount To Fair Value: 30.8%

TORIDOLL Holdings is trading at ¥3897, significantly below its estimated fair value of ¥5628.67, suggesting it could be undervalued based on cash flows. Earnings are expected to grow substantially by 44.7% annually, outpacing the Japanese market's average growth rate. However, recent guidance revisions show lowered profit expectations due to underperformance in its overseas segment despite strong domestic results from Marugame Seimen, which may concern some investors regarding future profitability.

TSE:3397 Discounted Cash Flow as at Dec 2024
TSE:3397 Discounted Cash Flow as at Dec 2024

Key Takeaways

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com